CR20190540A - FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069) - Google Patents

FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069)

Info

Publication number
CR20190540A
CR20190540A CR20190540A CR20190540A CR20190540A CR 20190540 A CR20190540 A CR 20190540A CR 20190540 A CR20190540 A CR 20190540A CR 20190540 A CR20190540 A CR 20190540A CR 20190540 A CR20190540 A CR 20190540A
Authority
CR
Costa Rica
Prior art keywords
vaccine formulations
norovirus vaccine
parenteral
parenteral norovirus
compositions
Prior art date
Application number
CR20190540A
Other languages
English (en)
Inventor
Charles Richardson
Robert F Bargatze
Paul M Mendelman
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47506489&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190540(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CR20190540A publication Critical patent/CR20190540A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones de vacuna parenterales de dosis individuales que comprenden mezclas de partículas tipo virus monovalentes de Norovirus. También se divulgan métodos para conferir una inmunidad protectora contra infecciones por Norovirus en un ser humano por administración de dichas composiciones.
CR20190540A 2011-07-11 2012-07-11 FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069) CR20190540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506447P 2011-07-11 2011-07-11
PCT/US2012/046222 WO2013009849A1 (en) 2011-07-11 2012-07-11 Parenteral norovirus vaccine formulations

Publications (1)

Publication Number Publication Date
CR20190540A true CR20190540A (es) 2022-04-04

Family

ID=47506489

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190540A CR20190540A (es) 2011-07-11 2012-07-11 FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069)
CR20140069A CR20140069A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140069A CR20140069A (es) 2011-07-11 2014-02-11 Formulaciones parenterales de vacunas contra los norovirus

Country Status (29)

Country Link
US (5) US9801934B2 (es)
EP (3) EP4112074A1 (es)
JP (2) JP6208659B2 (es)
KR (1) KR102096937B1 (es)
CN (3) CN105031637A (es)
AU (2) AU2012282658B2 (es)
BR (1) BR112014000656A2 (es)
CA (1) CA2841356C (es)
CL (1) CL2014000082A1 (es)
CR (2) CR20190540A (es)
DK (1) DK3299030T3 (es)
DO (2) DOP2014000004A (es)
EA (3) EA035442B1 (es)
EC (1) ECSP14013201A (es)
ES (2) ES2656527T3 (es)
GE (1) GEP201706668B (es)
HK (3) HK1198136A1 (es)
IL (1) IL230356B (es)
MA (1) MA35414B1 (es)
MX (1) MX356586B (es)
MY (1) MY170746A (es)
PE (1) PE20140845A1 (es)
PH (1) PH12018501515B1 (es)
PL (2) PL2731621T3 (es)
SG (1) SG10201605644WA (es)
TN (1) TN2014000008A1 (es)
UA (1) UA117732C2 (es)
WO (1) WO2013009849A1 (es)
ZA (2) ZA201401012B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174845A1 (en) 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
ES2656527T3 (es) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
EP3085357B1 (en) 2013-12-16 2019-02-13 Takeda Pharmaceutical Company Limited Microneedle
CN107184970A (zh) * 2017-02-16 2017-09-22 北京生物制品研究所有限责任公司 口服诺如病毒亚单位疫苗及lt作为该疫苗佐剂的用途
GB201703644D0 (en) 2017-03-07 2017-04-19 Elopak As Improvements in or relating to toller mounting arrangements
WO2018210804A1 (en) * 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3752185A1 (en) * 2018-02-15 2020-12-23 Icon Genetics GmbH Immunogenic composition and vaccine for generating an immune response to norovirus
WO2019231712A1 (en) * 2018-05-29 2019-12-05 Stc.Unm Virus-like particle compositions and methods of using same
CN109265542B (zh) * 2018-09-27 2021-06-15 国药中生生物技术研究院有限公司 特异性结合诺如病毒gii.4基因型vp1蛋白或vlp的抗体及其制备方法和应用
AR117462A1 (es) * 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
US20230285534A1 (en) * 2020-01-08 2023-09-14 Bharat Biotech International Limited Viral vaccine compositions and methods of preparations thereof
CA3213547A1 (en) 2021-03-29 2022-10-06 Naoshi Fukushima Peptide of norovirus origin, polynucleotide, antibody, composition, method for identifying neutralizing epitope for norovirus
JP2024519800A (ja) 2021-05-21 2024-05-21 タケダ ワクチン，インコーポレイテッド 固体組成物、フリーズドライ方法およびガラスバイアル
CN118252924A (zh) * 2022-12-27 2024-06-28 远大赛威信生命科学(南京)有限公司 用于诱发哺乳动物针对诺如病毒的免疫反应的药物组合物及其制备方法和用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572862B1 (en) 1989-11-08 2003-06-03 Baylor College Of Medicine Methods and reagents to detect and characterize Norwalk and related viruses
WO1992016543A1 (en) 1991-03-25 1992-10-01 Genelabs Incorporated NORWALK VIRUS HUMAN GASTROENTERITIS AGENT AND MOLECULAR CLONING OF CORRESPONDING cDNAs
AU683211B2 (en) 1992-04-08 1997-11-06 United States of America as represented by The Secretary Department of Health and Human Services, The Wild-type measles virus glycoproteins: vaccine and detection method therefor
WO1994005700A2 (en) 1992-09-07 1994-03-17 Baylor College Of Medicine Methods and reagents to detect and characterize norwalk and related viruses
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
US5788970A (en) 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5861241A (en) 1995-08-16 1999-01-19 University Of Massachusetts Monoclonal antibodies for detecting Norwalk virus
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
PL336715A1 (en) 1997-04-08 2000-07-03 Merck & Co Inc Stabilised formulation of human papilloma virus
EP0980257A1 (en) 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
US20040265377A1 (en) 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
BR9913026A (pt) 1998-08-14 2001-09-25 Merck & Co Inc Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
ES2262359T3 (es) 1998-12-17 2006-11-16 MERCK & CO., INC. Particulas tipo virus sinteticas con epitores heterologos.
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
CA2375337C (en) 1999-06-22 2012-09-25 Naokazu Takeda Srsv detection kit
JP2002020399A (ja) 2000-07-10 2002-01-23 Osaka Prefecture ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP4902103B2 (ja) 2002-04-11 2012-03-21 メディミューン・エルエルシー 凍結乾燥フォームによる生物活性材料の保存
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1545625B1 (en) 2002-06-07 2011-08-24 Kentucky Bioprocessing, LLC Flexible vaccine assembly and vaccine delivery platform
JP4598519B2 (ja) 2002-06-20 2010-12-15 サイトス バイオテクノロジー アーゲー アジュバントとして使用するためのパッケージ化されたウィルス様粒子：調製法及び使用法
WO2004075829A2 (en) 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
WO2004073652A2 (en) 2003-02-20 2004-09-02 Becton Dickinson And Company Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
JP2007537137A (ja) 2003-09-24 2007-12-20 モンタナ ステート ユニバーシティ ノロウィルスモノクローナル抗体及びペプチド
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
CU23496A1 (es) 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EA015907B1 (ru) 2004-10-20 2011-12-30 Санофи Пастер Байолоджикс Ко. Рекомбинантный флавивирус и его применение
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006203985A1 (en) 2005-01-05 2006-07-13 Philadelphia Health And Education Corporation Delivery vehicles, bioactive substances and viral vaccines
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
BRPI0608455A2 (pt) 2005-03-18 2010-01-05 Cytos Biotechnology Ag composição compreendendo conjugados de alérgenos de gato bem como vacinas, composições farmacêuticas e medicamentos contendo a mesma, e processo para sua produção
US20070041999A1 (en) 2005-06-01 2007-02-22 Lada Rasochova Production of multivalent virus like particles
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
JP2007145775A (ja) 2005-11-29 2007-06-14 Falco Life Science:Kk ノロウイルスｇｉの高感度検出方法
US20080029915A1 (en) * 2006-08-02 2008-02-07 Courtoy Nv Rotary tablet press
SG174845A1 (en) * 2006-09-29 2011-10-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
KR20150098681A (ko) * 2007-03-14 2015-08-28 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
WO2009033229A1 (en) 2007-09-12 2009-03-19 Australian Centre For Plant Functional Genomics Pty Ltd Plant seed active transcriptional control sequences
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
WO2010084298A1 (en) * 2009-01-22 2010-07-29 Pharmathene Uk Limited Stable vaccine compositions and methods of use
KR20110132373A (ko) * 2009-02-10 2011-12-07 노파르티스 아게 유행병-연관 주에 대한 인플루엔자 백신 요법
US20110070260A1 (en) 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
JP2013517773A (ja) * 2010-01-21 2013-05-20 リゴサイト ファーマスーティカルズ，インコーポレイテッド カリシウイルスウイルス様粒子上の標的化異種抗原提示
CA2798493A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Synthetic nanocarrier combination vaccines
ES2656527T3 (es) 2011-07-11 2018-02-27 Takeda Vaccines, Inc. Formulaciones parenterales de vacunas de norovirus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
US10975149B2 (en) 2015-12-16 2021-04-13 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
BR112020022010A2 (pt) 2018-05-03 2021-01-26 Board Of Regents, The University Of Texas System células exterminadoras naturais modificadas para expressar receptores de antígeno quimérico com bloqueio de checkpoint imunológico
WO2020041192A1 (en) 2018-08-20 2020-02-27 Takeda Vaccines, Inc. Vlp formulations
AR117462A1 (es) 2018-12-20 2021-08-04 Takeda Vaccines Inc Vacuna contra norovirus, formulaciones y métodos
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia

Also Published As

Publication number Publication date
US11701420B2 (en) 2023-07-18
JP2014520852A (ja) 2014-08-25
AU2012282658B2 (en) 2014-11-27
CN103874507A (zh) 2014-06-18
TN2014000008A1 (en) 2015-07-01
US9867876B2 (en) 2018-01-16
DOP2022000030A (es) 2022-06-30
EP2731621B1 (en) 2017-11-01
DK3299030T3 (da) 2022-09-05
EP3299030A1 (en) 2018-03-28
CN105031637A (zh) 2015-11-11
CA2841356A1 (en) 2013-01-17
JP6208659B2 (ja) 2017-10-04
CA2841356C (en) 2022-03-01
SG10201605644WA (en) 2016-09-29
NZ620865A (en) 2015-08-28
KR102096937B1 (ko) 2020-04-03
NZ710919A (en) 2017-12-22
US20160000899A1 (en) 2016-01-07
CN108567975A (zh) 2018-09-25
ES2926487T3 (es) 2022-10-26
IL230356B (en) 2019-05-30
CR20140069A (es) 2014-06-27
US20180185468A1 (en) 2018-07-05
EP3299030B1 (en) 2022-06-08
EA202090699A3 (ru) 2020-11-30
EA202090699A2 (ru) 2020-07-31
KR20140066160A (ko) 2014-05-30
HK1198136A1 (en) 2015-03-13
EA029470B1 (ru) 2018-03-30
US20230338503A1 (en) 2023-10-26
US20210085778A1 (en) 2021-03-25
GEP201706668B (en) 2017-05-25
ZA201401012B (en) 2015-05-27
EA035442B1 (ru) 2020-06-17
BR112014000656A2 (pt) 2017-02-14
JP2017214357A (ja) 2017-12-07
ECSP14013201A (es) 2014-05-31
DOP2014000004A (es) 2014-10-31
EA201792407A2 (ru) 2018-03-30
EP2731621A1 (en) 2014-05-21
CL2014000082A1 (es) 2014-07-04
ZA201500915B (en) 2016-06-29
ES2656527T3 (es) 2018-02-27
AU2012282658A1 (en) 2013-03-14
MX356586B (es) 2018-06-05
JP6613259B2 (ja) 2019-11-27
PL3299030T3 (pl) 2022-12-05
US20130273102A1 (en) 2013-10-17
US9801934B2 (en) 2017-10-31
AU2015200836B2 (en) 2016-08-25
PE20140845A1 (es) 2014-08-03
EA201490258A1 (ru) 2014-05-30
MA35414B1 (fr) 2014-09-01
PH12018501515A1 (en) 2019-02-04
US10675341B2 (en) 2020-06-09
HK1215154A1 (zh) 2016-08-19
MX2014000411A (es) 2014-08-26
EA201792407A3 (ru) 2018-07-31
EP4112074A1 (en) 2023-01-04
HK1199202A1 (en) 2015-06-26
PH12018501515B1 (en) 2019-02-04
AU2015200836A1 (en) 2015-03-12
EP2731621A4 (en) 2015-03-25
PL2731621T3 (pl) 2018-10-31
WO2013009849A1 (en) 2013-01-17
MY170746A (en) 2019-08-27
UA117732C2 (uk) 2018-09-25

Similar Documents

Publication Publication Date Title
PH12018501515A1 (en) Parenteral novovirus vaccine formulations
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
MX2012009581A (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
GB201400609D0 (en) Vaccine adjuvant composition comprising inulin particles
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
EA032913B1 (ru) Препараты производных пиримидиндиона
EA201690378A1 (ru) Вакцинные композиции против наркотической зависимости
EP2780009A4 (en) METHODS AND COMPOSITIONS FOR ENHANCED IL-MEDICATION ADMINISTRATION AND EXTENDED DELIVERY FORMULATIONS
IN2013CH04314A (es)
PH12015500708A1 (en) Agent for enhancing immunity containing glutathione
UA106101C2 (uk) Спосіб виготовлення медичних противірусних препаратів, що містять наночастинки, та препарат проти вірусів герпесу hiv і грипу h1n1, виготовлений за даним способом
IN2013MU03123A (es)
EP2777712A4 (en) AUXILIARY SUBSTANCES FOR POLYSACCHARIDIVES AND FORMULATIONS OBTAINED THEREFROM
UA106111C2 (uk) Спосіб отримання людського інтерферону з використанням наночастинок оксиду церію